Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6-an evaluation with the nonparametric maximum likelihood method.
Open Access
- 1 November 1994
- journal article
- Published by Wiley
- Vol. 38 (5) , 453-462
- https://doi.org/10.1111/j.1365-2125.1994.tb04382.x
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Genetically variable metabolism of antidepressants and neuroleptic drugs in manPharmacogenetics, 1993
- Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquineThe Lancet, 1993
- d-Propoxyphene is a Potent Inhibitor of Debrisoquine, but Not S-Mephenytoin 4-Hydroxylation In VivoTherapeutic Drug Monitoring, 1990
- Steady state pharmacokinetics of nortriptyline in the frail elderlyNeuropsychopharmacology, 1989
- Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in manLife Sciences, 1980
- Pharmacokinetics of Single Oral Doses of Nortriptyline in Depressed Elderly Hospital Patients and Young Healthy VolunteersClinical Pharmacokinetics, 1980
- Individual Differences in the Disposition of Drugs Metabolised in the BodyClinical Pharmacokinetics, 1978
- Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics: A study in twinsEuropean Journal of Clinical Pharmacology, 1973
- PLASMA-NORTRIPTYLINE LEVELS IN ENDOGENOUS DEPRESSIONThe Lancet, 1973